Corrigendum: Cost-Effective, Safe, and Personalized Cell Therapy for Critical Limb Ischemia in Type 2 Diabetes Mellitus (Frontiers in Immunology, (2019), 10, 10.3389/fimmu.2019.01151)

Abstract

In the original article, there were multiple errors. The corresponding author emails karim.hmadcha@cabimer.es and bernat.soria@cabimer.es are no longer operational and should be replaced as follows: Abdelkrim Hmadcha khmadcha@gmail.com; khmadcha@upo.es Bernat Soria bernat.soria@umh.es; bsoresc@acu.upo.es We further neglected to indicate the funder “Juvenile Diabetes Research Foundation, JDRF 2-SRA-2019-837-S-B I” to Bernat Soria. In the published article, as well as having Affiliations 2 and 3, Bernat Soria should also have an additional affiliation “ISABIAL and Institute of Bioengineering, University Miguel Hernández de Elche, Alicante, Spain.” Corrections have been made to the References. Reference 67 was incorrectly included as “Riera MLS A. A., Stefanov K. S., Tong H., Riera C. L., García-Olmo D., García-Arranz M. Phase Ib Open Clinical Trial to Assess the Safety of Autologous Mesenchymal Stem Cells for the Treatment of Nonrevascularizable Critical Lower Limb Ischemia. J Stem Cell Res Ther. (2017) 7:391.”. Instead, it should be “Riera ML, Salazar AA, Stefanov KS, Tong H, Riera CL, García-Olmo D, et al. Phase Ib open clinical trial to assess the safety of autologous mesenchymal stem cells for the treatment of nonrevascularizable critical lower limb ischemia. J Stem Cell Res Ther. (2017) 7:391. doi: 10.4172/2157-7633.1000391.”